Company Monitoring Page for Alkermes

latest headlines for company on cafepharma

Alkermes Breaks $1 Billion
Motley Fool
Tue, 02/19/19 - 12:18 pm
Tags:
Alkermes, earnings
Alkermes shares take another hit as the FDA shakes its head — again — on a weak case for '5461
Endpoints
Fri, 02/1/19 - 10:41 pm
Tags:
Alkermes, FDA, ALKS-5461
Down but Not Out: 10 Biggest Drug Trials That Saw Challenges in 2018
BioSpace
Fri, 12/21/18 - 12:10 pm
Tags:
clinical trials, Takeda, Zinfandel Pharmaceuticals, pioglitazone, Alzheimer's disease, Boehringer Ingelheim, BI 409306, Merck, verubecestat, Celgene, MS, ozanimod, Incyte, ID01, melanoma, vTv Therapeutics, azeliragon, Roche, Tecentriq, Exelixis, colorectal cancer, JNJ, atabacestat, Sareptat Therapeutics, DMD, Exondys 51, Alkermes, ALKS-5461, clinical depression
Alkermes/Biogen hope for less tummy trouble with new MS pill
Pharmaforum
Tue, 12/18/18 - 10:28 am
Tags:
Alkermes, Biogen, MS, multiple sclerosis, Vumerity
Alkermes Schizophrenia Drug Heads To FDA, But Questions Linger
Xconomy
Thu, 11/29/18 - 09:37 am
Tags:
ALKS-3831, Alkermes, schizophrenia, FDA
[video+transcript]Why Alkermes' Depression Drug Stumbled, and How Illumina Plans to Profit From M&A
Motley Fool
Fri, 11/9/18 - 12:05 am
Tags:
Alkermes, depression, ALSK-5461, opioids, Illumina, Pacific Biosciences
More data could be key for Alkermes after FDA panel vote
BioCentury
Sat, 11/3/18 - 03:59 pm
Tags:
Alkermes, ALKS 5461, major depressive disorder, FDA
Alkermes Depression Drug Faces Long Odds After FDA Advisors Say No
Xconomy
Thu, 11/1/18 - 07:30 pm
Tags:
Alkermes, FDA, advisory panels, ALKS-5461, major depressive disorder
FDA Blasts Data, Trial Design For Alkermes Depression Drug
Xconomy
Tue, 10/30/18 - 11:34 am
Tags:
FDA, Alkermes, ALKS 5461, clinical trials, major depressive disorder
A double date with destiny for Alkermes
EP Vantage
Fri, 10/5/18 - 12:06 pm
Tags:
Alkermes, FDA, clinical trials, ALKS 5461, ALKS 3831
Alkermes in pay-for-performance deal
BioCentury
Sat, 09/1/18 - 04:10 pm
Tags:
Alkermes, UPMC, Vivitrol, opioids, opioid addiction, pay-for-performance
Alkermes, Oklahoma negotiating value-based Medicaid purchasing agreements
BioCentury
Sun, 08/26/18 - 11:58 am
Tags:
Oklahoma, Medicaid, Alkermes, Aristada, schizophrenia
Collaborations Help Alkermes Flip to Profitability
Motley Fool
Fri, 07/27/18 - 07:09 pm
Tags:
Alkermes, Biogen, earnings
FDA Now Accepts Alkermes Application It Rejected Two Weeks Ago
CP Wire
Mon, 04/16/18 - 09:05 am
Tags:
Alkermes, ALKS-5461, major depressive disorder, FDA
Mon, 04/16/18 - 08:50 am
Tags:
Alkermes, ALKS-5461
Alkermes' Bad News Could Be Good News for Johnson & Johnson
Motley Fool
Wed, 04/4/18 - 10:07 pm
Tags:
Alkermes, JNJ, ALKS-5461, esketamine, major depressive disorder
Why FDA News About Alkermes ALKS 5461 Studies Is Not A Complete Surprise
CP Wire
Mon, 04/2/18 - 09:37 am
Tags:
Alkermes, FDA, ALKS 5461, clinical trials
Mon, 04/2/18 - 09:33 am
Tags:
Alkermes, ALKS 5461, major depressive disorder
FDA Rejects Alkermes NDA for Major Depressive Disorder Drug ALKS 5461
CP Wire
Mon, 04/2/18 - 09:01 am
Tags:
Alkermes, FDA, depression, major depressive disorder, ALKS 5461
Trump opioid plan writes in favoritism to single company’s addiction medication
Stat
Mon, 03/26/18 - 10:08 am
Tags:
opioids, opioid crisis, opioid addiction, Donald Trump, Alkermes, Vivitrol

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.